Pharminox Ltd
www.pharminox.com
Pharminox is focused on the discovery and development of novel small molecule drugs for the treatment of cancer. In early 2004, Malcolm Stevens, Director of the Cancer Research UK Experimental Cancer Chemotherapy Group, joined Pharminox as Chief Scientific Officer. Their discovery activities are now based at their new laboratories at the BioCity facility in the centre of Nottingham.
Company History
January 2002 — Company established
- Spin out from Oxford University to exploit novel platinum complexes discovered by Professor Gordon Lowe of the Dyson Perrins Laboratory, Oxford.
- Founding investors include IP2IPO and University of Oxford
December 2003 — Preclinical portfolio expanded
- Pharminox licences worldwide development and commercialisation rights to Quinols from Cancer Research Technology (CRT) and enters into research collaboration with University of Nottingham and CRT
January 2004 — Board Strengthened
- Professor Malcolm Stevens OBE appointed as Chief Scientific Officer
- Sue Barrowcliffe appointed to the board
June 2004 — Additional funds raised
- 1.5million private funding round completed
July 2004 — Pharminox gains access to first clinical project
- Pharminox sign an option agreement with CRT, which provides a 12 month exclusive option to licence the global development and commercial rights to Phortress.
November 2004 — Board further strengthened
- Peter Worrall appointed as Chief Executive Officer